Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a...
WOBURN, Mass., May 31, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development...
TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and...
WOBURN, Mass., May 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development...
One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in...
WOBURN, Mass., May 29, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development...
Company discusses AI-assisted body-map monitoring architecture and long-term imaging technology development initiatives MESA, AZ / ACCESS Newswire / May 28,...
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and...
MDCE Strengthens Its Artificial Intelligence Expansion Strategy With New Healthcare Beta Preview and Multi-Sector Growth Initiatives MESA, AZ / ACCESS...
Rapid advances in artificial intelligence may create new opportunities for MDCE to expand technical capability while accelerating execution across its...
Partnership to deliver a novel AI-native integrated CNS oncology platform Platform will unify and analyze Plus’ proprietary therapeutic, diagnostic, and...
The trial did not reach statistical significance for the primary endpoint of improvement in progression-free survival (PFS) A numeric improvement...
The second annual #HatsonforAK Campaign runs May 18–24, 2026, culminating on Global Actinic Keratosis (AK) Awareness DayThis social media–driven initiative...
Live virtual fireside chat — investors, advisors, and life sciences analysts invited to attendFeaturing Dermatologist Mary Spellman, M.D., with Phio...
Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with Favorable Safety and Pathology DataKey...
Halo Care Skin Tag Remover Sanguinaria Canadensis and Zincum Muriaticum Formula Explained: 2026 Pricing, Refund, and Dermatologist GuidanceNew York, NY,...
Reports first quarter revenue of $0.4 billion, with approximately 80% of revenue from international marketsReports first quarter GAAP net loss...
Following a recent FSDPA speaking engagement, the Tampa-area dermatologist continues a spring schedule of community health initiatives and dermatology education...
First quarter 2026 revenues increased 19% to $3.6 billion versus first quarter 2025Dupixent® global net sales (recorded by Sanofi) increased...
Expands access by 6 million covered lives, advancing commercial momentum for CNSide® in metastatic CNS cancersHOUSTON, April 28, 2026 (GLOBE...